Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting

Inclusion Criteria: * Diagnosis of any form of Primary Immunodeficiency Disease * Males and Females * ≥ 15 and ≤ 85 years of age * 5% treatment Naïve IVIg for the treatment of PIDD * Ability to have Gammaplex® IVIg prescribed under the discretion of the patient's treating physician in accordance with standard treatment practices for the entire duration of the study * Ability and willingness to provide informed consent and comply with study requirements and procedures * Ability to read and write English * Understanding of study procedures and ability to comply with study procedures for the entire length of the study * Eligible for infusion services by AxelaCare Health Solutions, LLC, in collaboration with the subject's prescribing physician and insurance provider Exclusion Criteria: * The presence of any medical condition that the investigator and/or prescribing physician deems incompatible with participation in this trial. * Prisoners, and other wards of the state * Determined to have non-competency of data collection requirements (physical assessments and use of an iPAD™) by either the home infusion nurse and/or Caregiver. * Receiving Subcutaneous Immunoglobulin (SCIg) Therapy during study participation.